AIM-HI Accelerator Fund

On October 18, 2024, global leaders in the fight against #cancer gathered in Washington, DC, for the 2024 National Foundation for Cancer Research (NFCR) Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship, co-hosted by AIM-HI.  This prestigious event, held at the National Press Club, served as a unique forum for advancing groundbreaking science, fostering innovative #collaborations, identifying critical unmet needs for patients, and driving forward breakthrough #oncology solutions. Read our Event Recap: https://bit.ly/40myVNc Follow us as we share more video highlights from the event, too! Support Our Mission: https://bit.ly/47VzZJE #AIMHIaccelerator #WeDriveCuresForward #Innovation Webster Cavenee Patricia Obermaier Pamela Garzone, Ph.D. Dimitra Georganopoulou Beverly Lu, PhD Fei Shen David Greenwald, Ph.D. Marie-Claire Peakman

AIM-HI congratulates March Biosciences, led by CEO & Co-Founder Sarah Hein, Ph.D., the First Prize Winner with Distinction of our 2023 AIM-HI Women's Venture Competition, for closing a $28.4 million oversubscribed Series A financing. March Bio is an emerging clinical-stage #biotech company committed to combating challenging cancers and other diseases. Funds will support Phase 2 development of March Bio’s lead CD5 CAR-T therapy, MB-105, for T-cell lymphoma and pipeline candidates. Read More: https://bit.ly/4f10obZ The AIM-HI Women’s Venture Competition is a first-of-its-kind program that provides funding, coaching, and networking opportunities to women-led oncology startups. The competition’s review committees provided assessments and recommendations for recognizing the Women’s Venture Competition winners based on scientific and clinical merits and business impact for #cancer patients. Support Our Mission: https://bit.ly/47VzZJE #AIMHIaccelerator #WomenEmpowerment #DriveCuresForward Sujuan Ba Dimitra Georganopoulou Rose Wang Matt Tremblay, Ph.D. National Foundation for Cancer Research (NFCR) OncoDaily

The AIM-HI Accelerator Fund welcomes Mr. Silas Deane, Vice President at Tyler Technologies, to our Board of Directors. Mr. Deane, a long-time supporter and advocate of innovative cancer research, brings a wealth of expertise in technology, healthcare, and business development. His leadership and entrepreneurial background mark a significant addition to AIM-HI’s mission of advancing oncology-focused startups and accelerating breakthroughs in cancer treatments. “As cancer research advances, it’s becoming clear that innovation and early-stage investment are crucial to achieving real breakthroughs,” Mr. Deane remarked. “I’m honored to join AIM-HI’s Board and excited to contribute to their efforts in supporting pioneering companies that are poised to make a real difference in cancer treatment.” “Silas’s track record of driving technology and business innovation makes him a perfect fit for our Board,” said Dr. Sujuan Ba, CEO and Co-Founder of AIM-HI. “We’re looking forward to working together to propel our mission of accelerating promising cancer treatments and providing vital support to oncology startups.” Read More: https://bit.ly/3YjAc4X Support Our Mission: https://bit.ly/47VzZJE #AIMHIaccelerator #Oncology #Innovation #Entrepreneurship #DriveCuresForward National Foundation for Cancer Research (NFCR)

AIM-HI is proud to co-host the 2024 NFCR Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship with our partner organization, National Foundation for Cancer Research (NFCR), last Friday, October 18, 2024, at the National Press Club in Washington, DC. Highlights of the event include honoring Dr. Margaret Foti, CEO of American Association for Cancer Research, for the 2024 AIM-HI Beacon Award for Women's Leadership in Oncology; recognizing the 2024 AIM-HI Women's Venture Competition top winners: Nabanita Nawar, PhD of HDAX Therapeutics, First Prize with Distinction, Paraskevi (Evi) Giannakakou and CheukMan Cherie Au, Ph.D of ARMA BIO, Second Prize; and the Innovative Oncology Companies Showcase and Investor Perspective, moderated by Matt Tremblay, Ph.D., Chair of the AIM-HI Board and CEO of Blackbird Laboratories. We thank our speakers, attendees, sponsors, donors, and supporters for making this event possible and successful. Together, we can drive cures forward for cancer patients worldwide! #AIMHIaccelerator #CancerResearch #Oncology #Entrepreneurship #WomenInOncology #AIMHIBeaconAward OncoDaily Sujuan Ba

Join us in Congratulating Dr. Dennis Slamon on being selected as the 2024 Szent-Györgyi Prize Winner! Dr. Slamon's research is responsible for saving countless lives, and it is an honor to recognize him. #GSAC24 #Prize #Award #Congratulations #Cancer #Research #CancerResearch | UCLA Health

Our dinner award ceremony for the 2024 Szent-Györgyi Prize Winner is about to begin! Join us in congratulating Dr. Dennis Slamon, of UCLA Health, on this monumental achievement! #GSAC24 #NFCR #Cancer #Award #MakeCuresPossible #Stem UCLA Health |

The panel on the Investor Perspective is starting now! Our panelists insights into venture investments in the cancer research space is crucial in the fight against cancer. #GSAC24 #Venture #VentureCapital #Investment #Panel #GlobalSummit | Matt Tremblay, Ph.D. | David Greenwald, Ph.D. | Beverly Lu, PhD | Yosemite | Marie-Claire Peakman | Pfizer | Fei Shen | Boehringer Ingelheim

Please join us in congratulating the 2024 AIM-HI Women’s Venture Competition Award Winners: Nabanita Nawar, Ph.D., Co-Founder & CEO, HDAX Therapeutics, and Paraskevi Giannakakou, Ph.D. Co-Founder & CSO, ARMA Bio. #GSAC24 #EmpoweringWomen #WomenEntrepreneurs

Congratulations to Dr. Margaret Foti on receiving the AIM-HI Beacon Award! #GSAC24 | American Association for Cancer Research | #Research #CureCancer

Our first panel on New Approaches to Cancer Treatments has just begun. Thank you Dr. Lisa Coussens for starting emceeing this session and reminding us why new treatments are still so crucial! #GSAC24 #Cancer #CureCancer #NFCR